FoundationOne Liquid CDx: FDA status

Approved Approved Jul 1, 2024. Indication: Companion diagnostic for BRCA mutated metastatic castration resistant prostate cancer to identify patients for niraparib plus abiraterone. Company: Foundation Medicine.

Regulatory history

• Jul 1, 2024: Approved. FoundationOne Liquid CDx became an FDA approved companion diagnostic for niraparib and abiraterone acetate in BRCA mutated mCRPC. targetedonc.com

All products in the FDA Tracker